Corrigendum to “High expression of DLL3 is associated with a poor prognosis and immune infiltration in invasive breast cancer patients” [Translational Oncology 14 (2021) 101080]

The authors regret Figure 5A was misapplied in the originally published version of this article. It has been corrected and modified as follows. This error does not change scientific results and conclusions of the research.

Fig. 5.

DLL3 positively regulated P53 signaling pathway.

The authors would like to apologise for any inconvenience caused.